Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1736-1742

  Matzneller, P ^a   Krasniqi, S ^a   Kinzig, M ^b   Sorgel F ^b,c   Huttner S ^b   Lackner, E ^a   Muller M ^a   Zeitlinger, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b School of Medicine   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; DRUG BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNOMODULATION; LEUKOCYTE; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUBCUTANEOUS FAT; VIRULENCE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84875172402     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02011-12     Document Type: Article

References (59)

1. Coenen S, Ferech M, Malhotra-Kumar S, Hendrickx E, Suetens C, Goossens H. 2006. European Surveillance of Antimicrobial Consumption (ESAC): outpatient macrolide, lincosamide and streptogramin (MLS) use in Europe. J. Antimicrob. Chemother. 58:418-422.
2. Marra F, Patrick DM, Chong M, Bowie WR. 2006. Antibiotic use among children in British Columbia, Canada. J. Antimicrob. Chemother. 58: 830-839.
3. Andes D, Anon J, Jacobs MR, Craig WA. 2004. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin. Lab. Med. 24:477-502.
4. Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R. 1987. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob. Agents Chemother. 31:1939 -1947.
5. Pichereau S, Moran JJ, Hayney MS, Shukla SK, Sakoulas G, Rose WE. 2012. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J. Antimicrob. Chemother. 67:123-129.
6. Debbia EA, Molinari G, Paglia P, Schito GC. 1990. Post-antibiotic effect of azithromycin on respiratory tract pathogens. Drugs Exp. Clin. Res. 16:615-619.
7. Drew RH, Gallis HA. 1992. Azithromycin - spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 12:161-173.
8. Hand WL, Hand DL. 2001. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents 18:419-425.
9. McDonald PJ, Pruul H. 1991. Phagocyte uptake and transport of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10:828-833.
10. Amsden GW. 2001. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18(Suppl 1):S11-S15.
11. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25(Suppl A):73-82.
12. Lode H, Borner K, Koeppe P, Schaberg T. 1996. Azithromycin - review of key chemical, pharmacokinetic and microbiological features. J. Antimicrob. Chemother. 37(Suppl C):1-8.
13. Crokaert F, Hubloux A, Cauchie P. 1998. A phase I determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500 mg once daily for 3 days. Clin. Drug Invest. 16:161-166.
14. Kastner U, Guggenbichler JP. 2001. Influence of macrolide antibiotics on promotion of resistance in the oral flora of children. Infection 29:251-256.
15. De La Pena A, Dalla Costa T, Talton JD, Rehak E, Gross J, Thyroff-Friesinger U, Webb AI, Muller M, Derendorf H. 2001. Penetration of cefaclor into the interstitial space fluid of skeletal muscle and lung tissue in rats. Pharm. Res. 18:1310 -1314.
16. Ryan DM. 1993. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J. Antimicrob. Chemother. 31(Suppl D):1-16.
17. Lucchi M, Damle B, Fang A, de Caprariis PJ, Mussi A, Sanchez SP, Pasqualetti G, Del Tacca M. 2008. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. J. Antimicrob. Chemother. 61:884-891.
18. Olsen KM, San Pedro G, Gann LP, Gubbins PO, Halinski DM, Campbell GD, Jr. 1996. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40:2582-2585.
19. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. 1996. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40: 2375-2379.
20. Cazzola M, Siniscalchi C, Vinciguerra A, Santangelo G, Matera MG, Rossi F. 1994. Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. Int. J. Clin. Pharmacol. Ther. 32:88 -91.
21. Danesi R, Lupetti A, Barbara C, Ghelardi E, Chella A, Malizia T, Senesi S, Angeletti CA, Del Tacca M, Campa M. 2003. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1,000 mg. J. Antimicrob. Chemother. 51:939 -945.
22. Harrison JD, Jones JA, Morris DL. 1991. Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur. J. Clin. Microbiol. Infect. Dis. 10:862-864.
23. Morris DL, De Souza A, Jones JA, Morgan WE. 1991. High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose. Eur. J. Clin. Microbiol. Infect. Dis. 10:859-861.
24. Kent JR, Almond MK, Dhillon S. 2001. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit. Dial. Int. 21:372-377.
25. Wilms EB, Touw DJ, Heijerman HG. 2008. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J. Cyst. Fibros. 7:79-84.
26. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, Hammarlund-Udenaes M, Joukhadar C, Kellogg DL, Jr, Lunte CE, Nordstrom CH, Rollema H, Sawchuk RJ, Cheung BW, Shah VP, Stahle L, Ungerstedt U, Welty DF, Yeo H. 2007. AAPS-FDA workshop white paper: microdialysis principles, application, and regulatory perspectives. J. Clin. Pharmacol. 47:589-603.
27. Muller M. 2002. Science, medicine, and the future: microdialysis. BMJ 324:588 -591.
28. Nibbering PH, Zomerdijk TP, Corsel-Van Tilburg AJ, Van Furth R. 1990. Mean cell volume of human blood leucocytes and resident and activated murine macrophages. J. Immunol. Methods 129:143-145.
29. Krasniqi S, Matzneller P, Kinzig M, Sorgel F, Huttner S, Lackner E, Muller M, Zeitlinger M. 2012. Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy. Antimicrob. Agents Chemother. 56:1059 -1064.
30. Homma T, Fujimura T, Maki H, Yamano Y, Shimada J, Kuwahara S. 2010. In vitro antibacterial activities of S-013420, a novel bicyclolide, against respiratory tract pathogens. J. Antimicrob. Chemother. 65:1433-1440.
31. Bosnar M, Kelneric Z, Munic V, Erakovic V, Parnham MJ. 2005. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob. Agents Chemother. 49: 2372-2377.
32. Dunn CJ, Barradell LB. 1996. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 51:483-505.
33. Freeman CD, Nightingale CH, Nicolau DP, Belliveau PP, Banevicius MA, Quintiliani R. 1994. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob. Agents Chemother. 38:2449 -2451.
34. Amsden GW, Gray CL. 2001. Serum and WBC pharmacokinetics of 1,500mgof azithromycin when given either as a single dose or over a 3-day period in healthy volunteers. J. Antimicrob. Chemother. 47:61-66.
35. Bonnet M, Van der Auwera P. 1992. In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence. Antimicrob. Agents Chemother. 36:1302-1309.
36. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. 1989. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittelforschung 39:755-758.
37. Gladue RP, Snider ME. 1990. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob. Agents Chemother. 34:1056-1060.
38. Hoepelman IM, Schneider MM. 1995. Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 5:145-167.
39. Vaudaux BP, Cherpillod J, Dayer P. 1996. Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. J. Antimicrob. Chemother. 37(Suppl C):45-51.
40. Retsema JA, Bergeron JM, Girard D, Milisen WB, Girard AE. 1993. Preferential concentration of azithromycin in an infected mouse thigh model. J. Antimicrob. Chemother. 31(Suppl E):5-16.
41. Craig WA. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl 3): S233-S237.
42. Nightingale CH. 1997. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr. Infect. Dis. J. 16:438-443.
43. Frimodt-Moller N. 2002. How predictive is PK/PD for antibacterial agents? Int. J. Antimicrob. Agents 19:333-339.
44. Pfizer Corporation. 2009. Azithromycin summary of product characteristics. Pfizer Corporation, Vienna, Austria.
45. Arrieta A, Arguedas A, Fernandez P, Block SL, Emperanza P, Vargas SL, Erhardt WA, de Caprariis PJ, Rothermel CD. 2003. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob. Agents Chemother. 47:3179 -3186.
46. Casey JR, Pichichero ME. 2005. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. Clin. Infect. Dis. 40:1748 -1755.
47. Kogan R, Martinez MA, Rubilar L, Paya E, Quevedo I, Puppo H, Girardi G, Castro-Rodriguez JA. 2003. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children. Pediatr. Pulmonol. 35:91-98.
48. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. 2007. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369:482-490.
49. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. 2012. Azithromycin for prevention of exacerbations in noncystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 380:660-667.
50. Barbour A, Scaglione F, Derendorf H. 2010. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/ pharmacodynamic indices. Int. J. Antimicrob. Agents 35:431-438.
51. Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Muller M. 2000. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit. Care Med. 28:1754 -1759.
52. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M. 2001. Impaired target site penetration of betalactams may account for therapeutic failure in patients with septic shock. Crit. Care Med. 29:385-391.
53. Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E, Herrmann M, Riedmuller E, Muller M. 2001. Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin. Pharmacol. Ther. 70:532-539.
54. Gorby GL, McGee ZA. 1990. Antimicrobial interference with bacterial mechanisms of pathogenicity: effect of sub-MIC azithromycin on gonococcal piliation and attachment to human epithelial cells. Antimicrob. Agents Chemother. 34:2445-2448.
55. Molinari G, Guzman CA, Pesce A, Schito GC. 1993. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 31:681-688.
56. Shryock TR, Mortensen JE, Baumholtz M. 1998. The effects of macrolides on the expression of bacterial virulence mechanisms. J. Antimicrob. Chemother. 41:505-512.
57. Tateda K, Hirakata Y, Furuya N, Ohno A, Yamaguchi K. 1993. Effects of sub-MICs of erythromycin and other macrolide antibiotics on serum sensitivity of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 37:675-680.
58. Kovaleva A, Remmelts HH, Rijkers GT, Hoepelman AI, Biesma DH, Oosterheert JJ. 2012. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J. Antimicrob. Chemother. 67:530 -540.
59. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. 2012. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 68:479 -503.